Entero Therapeutics, Inc. Cash Flow-to-Debt Ratio
Entero Therapeutics, Inc. cash flow-to-debt ratio. Entero Therapeutics, Inc. (ENTO) has a Cash Flow-to-Debt Ratio of -0.02x as of September 2025, meaning its operating cash flow of $-855.69K could theoretically repay 0% of its total liabilities ($45.81 Million) in one year. Check Entero Therapeutics, Inc. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Entero Therapeutics, Inc. (2013–2024)
Cash flow-to-debt ratio of Entero Therapeutics, Inc. from 2013 to 2024. Historical debt coverage capacity for Entero Therapeutics, Inc. across 12 annual periods. Check how aggressively does Entero Therapeutics, Inc. reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Entero Therapeutics, Inc. Cash Flow-to-Debt Ratio by Year (2013–2024)
Entero Therapeutics, Inc. cash flow-to-debt ratio by year from 2013 to 2024. Year-by-year debt coverage analysis for Entero Therapeutics, Inc.. For the full cash flow conversion analysis, see Entero Therapeutics, Inc. (ENTO) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.33x | $-9.22 Million | $27.61 Million | ▲ +91.2% |
| 2023 | -3.77x | $-12.38 Million | $3.28 Million | ▲ +54.4% |
| 2022 | -8.28x | $-22.34 Million | $2.70 Million | ▼ -403.1% |
| 2021 | -1.65x | $-32.29 Million | $19.61 Million | ▼ -128.4% |
| 2020 | -0.72x | $-11.22 Million | $15.56 Million | ▼ -21917.4% |
| 2019 | 0.00x | $-14.03K | $4.29 Million | ▲ +99.9% |
| 2018 | -3.63x | $-10.87 Million | $3.00 Million | ▼ -92.9% |
| 2017 | -1.88x | $-7.18 Million | $3.82 Million | ▼ -46.9% |
| 2016 | -1.28x | $-4.53 Million | $3.54 Million | ▼ -316700.7% |
| 2015 | 0.00x | $-4.17K | $10.32 Million | ▼ -57.0% |
| 2014 | 0.00x | $-1.01K | $3.93 Million | ▼ -100.4% |
| 2013 | 0.06x | $56.55 | $939.30 | — |